Belle Gibson W
hen the fly agaric appeared on pharmacy shelves in 2022, not as a warning illustration but as a product ingredient, it represented something the mycology
community had not quite anticipated. A mushroom with 6,000 years of documented human use, studied by mycologists, ethnobotanists, and toxicologists for generations, had become a mainstream consumer item. Today muscimol gummies are sold in gas stations and supplement shops across most of the United States. Some carry third-party Certificates of Analysis. Many do not. Most consumers cannot explain what muscimol is or how it is made. Tis is a situation the mycology community is positioned to
address clearly. Tis article covers the chemistry that makes the modern Amanita muscaria product category possible, the regulatory framework that governs (and mostly doesn’t govern) it, and what the FDA’s December 2024 action actually means, because the coverage of that action has left consumers more confused than informed.
How the product category emerged Te shift from foraged A. muscaria to consumer gummies
was not an obvious development. Raw Amanita muscaria is dominated by ibotenic acid, a prodrug that is roughly four to ten times more toxic than muscimol and produces the nausea, delirium, and unpredictable reactions historically associated with the mushroom (Michelot and Melendez-Howell, 2003). Te traditional Siberian use involving urine recycling was,
22 FUNGI Volume 19:2 Summer 2026
in part, an early attempt to manage this conversion: ibotenic acid decarboxylates to muscimol in the body, and urine from someone who had consumed the mushroom contains higher muscimol concentrations (Wasson, 1968). Modern production inverts this process. Ibotenic acid
decarboxylates to muscimol through heat and changes in pH (Aranko et al., 1985). Manufacturers apply controlled heat, typically 60–80ºC in an acidic environment, to convert the mushroom’s ibotenic acid content before extraction. Te resulting extract is then incorporated into an edible format. Te claim, when it is made honestly, is that the product contains extracted muscimol rather than the raw alkaloid profile of the mushroom itself. What this means in practice depends almost entirely on
the quality of the conversion process and third-party testing. Incomplete decarboxylation leaves residual ibotenic acid in the final product. A product labeled “5 mg muscimol” may contain any ratio of muscimol to ibotenic acid depending on manufacturing quality. Since muscimol is the intended active compound and ibotenic acid is the toxicological concern, this distinction matters in a way that does not hold for most food supplements.
The testing gap Certificates of Analysis for muscimol products vary widely.
Some test for muscimol content only; others test for both muscimol and ibotenic acid and report a conversion ratio; others test for neither, relying instead on heavy metals, microbial counts, and pesticide panels that tell the consumer
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52
